Canada: The European Society of Cardiology (ESC) has taken a significant stride in the field of heart failure management with a focused update to their heart failure guidelines. This update incorporates crucial data from nearly a dozen new clinical trials that have been published since 2021. The trials include notable studies such as EMPEROR-Preserved, DELIVER, STRONG-HF, IRONMAN, and more. The updated guidelines, which were unveiled on the opening day of the ESC Congress 2023, offer novel recommendations related to the use of SGLT2 inhibitors in patients with heart failure and updates on comorbidity management.
New Recommendations:
Leave a reply